|
|
|
|
|
|
|
|
|
18.03.25 - 14:15
|
Lexarias DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lillys Injectable Zepbound (The Newswire)
|
|
|
More consistent accumulation demonstrated in bloodstream over a one-week duration with once-daily DehydraTECH-tirzepatide oral capsules as compared to once-weekly injection of Zepbound
As previously announced, oral DehydraTECH-tirzepatide also reduced adverse events by 47% compared to injected Zepbound
Lexaria's oral capsules worthy of expanded investigation as a viable alternative to injected tirzepatide.
Kelowna, British Columbia – March 18, 2025 – TheNewswire - Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce positive pharmacokinetic (“PK”) results from Human Study #3 or GLP-1-H24-3 (the “Study”), comparing an oral version of DehydraTECH-processed Zepbound® (“DehydraTECH-tirzepatide”) to conventional injected Zepbound®.
Zepbound® is currently only available as a once-weekly injection for weight loss. It is not sold by Eli Lilly in...
|
|
|
|
|
|
|
|
|
|
|
13.03.25 - 13:03
|
HAYA Therapeutics Appoints Former Exscientia Executive Dr. Richard Law as Chief Business Officer (Business Wire)
|
|
|
Former Exscientia executive who helped build the company and facilitate its merger with Recursion Pharmaceuticals joins to accelerate HAYA's strategic business operations and partnering
LAUSANNE, Switzerland & SAN DIEGO--(BUSINESS WIRE)--#Exscientia--HAYA Therapeutics, SA, a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics for rare, common, and chronic diseases, announced that Dr. Richard Law has joined as Chief Business Officer. With more than two decades of experience in drug discovery and business development, Dr. Law brings tremendous expertise in creating biopharma partnerships, shepherding company growth, and securing life sciences funding.
“In recent months, HAYA has reached significant milestones with our regulatory genome RNA-guided platform, including the announcement of our collaboration with Eli Lilly and Company,” said Samir Ounzain, Ph.D., Co-founder and CEO of HAYA Therapeutics. “As we continue our rapid growth and expansion into new dise...
|
|
|
|
|
|
|
|
|
|
|
|
|
11.03.25 - 15:36
|
Entos Pharmaceuticals Announces $198.5 Million Partnership with the Governments of Canada and Alberta to Accelerate Biomanufacturing of Fusogenix PLV Next Generation Therapeutics (Business Wire)
|
|
|
This investment will help build a 103,000-square-foot R&D center and a GMP manufacturing facility in Edmonton, Alberta.
The biomanufacturing facility will develop and produce the Entos Fusogenix PLV drug delivery platform and the next generation of medicines.
EDMONTON, Alberta--(BUSINESS WIRE)--#Fusogenix--Entos® Pharmaceuticals (Entos), a clinical-stage genetic medicines company committed to using its Fusogenix™ PLV™ technology to develop cures and improve the lives of patients and their families, announced a $62 million investment from the Government of Canada. This further leverages the previously announced $15.5 million awarded to Entos from the Government of Alberta.
The $77.5 million total investment will support a $198.5 million project to create a state-of-the-art R&D centre and GMP biomanufacturing facility in Edmonton, Alberta, Canada. The project builds on the significant partnership Entos has with global healthcare leader Eli Lilly & Company to research, develop, and commercialize nucleic...
|
|
|
|
|
|
|
|
|
10.03.25 - 21:33
|
Redwire Corporation Reports Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
|
|
|
Revenues for full year 2024 increased 24.7% year-over-year to $304.1 million
2024 accomplishments included securing a follow-on order of Roll-Out Solar Arrays for Thales Alenia Space, receiving a DARPA prime contract for our SabreSat VLEO platform, and launching 27 PIL-BOXes for our partners including Bristol Myers Squibb, Eli Lilly, and ExesaLibero Pharma
In January 2025, announced agreement to acquire Edge Autonomy in a transformational transaction that is expected to create a multi-domain, scaled and profitable space and defense tech company
Significant sequential increase in net cash provided by operations to positive $7.1 million and Free Cash Flow1 to positive $3.0 million for the fourth quarter of 2024
Net Loss for full year 2024 was $(114.3) million and Adjusted EBITDA1 for full year 2024 was $(0.8) million
JACKSONVILLE, Fla.--(BUSINESS WIRE)--Redwire Corporation (NYSE: RDW, the “Company”), a leader in space infrastructure for the next generation space economy, today announced results for its ...
|
|
|
10.03.25 - 16:33
|
Eli Lilly Aktie: Orfor-Phase-3-Daten im Fokus (Aktiencheck)
|
|
|
New York (www.aktiencheck.de) - Eli Lilly-Aktienanalyse von Morgan Stanley:
Rating und Kursziel
Morgan Stanley hat ein "overweight"-Rating für Eli Lilly and Company (ISIN: US5324571083, WKN: 858560, Ticker-Symbol: LLY, NYSE-Symbol: LLY) und setzt das Kursziel auf 1.146 USD. Die Analysten sehen trotz neuer Studiendaten von Novo Nordisk nur begrenzte Auswirkungen auf die Aktie von Eli Lilly. [mehr]...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
